Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kringle Pharma, Inc. (4884.T)
Ibaraki, JP
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.59% | -6.65% | -3.55% | +7.41% | +1.40% | +10.97% | -45.01% | -46.30% | -50.85% | -63.84% | -63.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-9.8% Q1'26: +2.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-13.3% Q1'26: +1.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-183.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,259.4% Q1'26: -1,736.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +197.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.9% Q1'26: +6.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
289.76M
est: 133.00M (+117.9%)
|
391.83M
est: 55.00M (+612.4%)
|
69.25M
est: 68.00M (+1.8%)
|
80.04M
est: 1.07B (-92.5%)
|
72.22M
est: 1.17B (-93.8%)
|
1.07B
1.07B – 1.07B
-8.6% YoY
|
4.07B
4.07B – 4.07B
+280.9% YoY
|
| EBITDA |
-357.88M
est: -133.00M (-169.1%)
|
-426.17M
est: -55.00M (-674.8%)
|
-888.76M
est: -68.00M (-1,207.0%)
|
-817.88M
est: -1.07B (+23.4%)
|
-909.45M
est: -1.17B (+22.1%)
|
-1.07B
-1.07B – -1.07B
+8.6% YoY
|
-4.07B
-4.07B – -4.07B
-280.9% YoY
|
| EBIT |
-357.88M
est: -133.00M (-169.1%)
|
-426.17M
est: -55.00M (-674.8%)
|
-888.76M
est: -68.00M (-1,207.0%)
|
-817.88M
est: -1.07B (+23.4%)
|
-909.45M
est: -1.17B (+22.1%)
|
-1.07B
-1.07B – -1.07B
+8.6% YoY
|
-4.07B
-4.07B – -4.07B
-280.9% YoY
|
| Net Income |
-301.17M
est: -1.83B (+83.5%)
|
-331.83M
est: -2.75B (+88.0%)
|
-854.15M
est: -1.21B (+29.5%)
|
-756.45M
est: 61.58M (-1,328.4%)
|
-916.26M
est: 109.47M (-937.0%)
|
-136.84M
-136.84M – -136.84M
-225.0% YoY
|
1.96B
1.96B – 1.96B
+1,530.0% YoY
|
| SGA |
177.52M
est: 568.53M (-68.8%)
|
196.29M
est: 235.11M (-16.5%)
|
241.22M
est: 290.68M (-17.0%)
|
254.65M
est: 2.55B (-90.0%)
|
300.31M
est: 2.79B (-89.2%)
|
2.55B
2.55B – 2.55B
-8.6% YoY
|
9.71B
9.71B – 9.71B
+280.9% YoY
|
| EPS |
-69.48
est: -267.10 (+74.0%)
|
-68.33
est: -402.50 (+83.0%)
|
-158.46
est: -177.00 (+10.5%)
|
-118.21
est: 9.00 (-1,413.4%)
|
-133.92
est: 16.00 (-937.0%)
|
-20.00
-20.00 – -20.00
-225.0% YoY
|
286.00
286.00 – 286.00
+1,530.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daichika Hayata | GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director | — | male |
| Kiichi Adachi | President, Chief Executive Officer & Chairman | — | male |
| Koichi Murakami | Director of Business Administration Dept., Business Management Dept. Manager & Director | — | male |
| Matt Vogelhuber | President of Kringle Pharma USA Inc. | — | male |
| Yoshiyuki Kayano | Director & GM of Quality Assurance Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4884.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
